Cingulate Inc. — Investor Relations & Filings
Filings indexed
445
across all filing types
Latest filing
2026-04-14
Registration Form
Country
US
United States of America
Listing
US
CING
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The company utilizes its proprietary Precision Timed Release (PTR) drug delivery platform, a novel erosion-based technology, to create medications with a true once-daily dosing profile. This platform is designed to provide controlled drug release for entire active-day efficacy. Cingulate's pipeline includes product candidates CTX-1301 and CTX-1302 for the ADHD market, and CTX-2103 for the anxiety market.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3 - Cingulate Inc. (0001862150) (Filer) | 2026-04-14 | English | |
| EFFECT - Cingulate Inc. (0001862150) (Filer) | 2026-03-27 | English | |
| SCHEDULE 13D/A - Cingulate Inc. (0001862150) (Subject) | 2026-03-26 | English | |
| EFFECT - Cingulate Inc. (0001862150) (Filer) | 2026-03-25 | English | |
| 8-K - Cingulate Inc. (0001862150) (Filer) | 2026-03-24 | English | |
| 424B3 - Cingulate Inc. (0001862150) (Filer) | 2026-03-24 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 34528394 | S-3 - Cingulate Inc. (0001862150) (Filer) | 2026-04-14 | English | ||
| 33057396 | EFFECT - Cingulate Inc. (0001862150) (Filer) | 2026-03-27 | English | ||
| 33052100 | SCHEDULE 13D/A - Cingulate Inc. (0001862150) (Subject) | 2026-03-26 | English | ||
| 33038981 | EFFECT - Cingulate Inc. (0001862150) (Filer) | 2026-03-25 | English | ||
| 33035416 | 8-K - Cingulate Inc. (0001862150) (Filer) | 2026-03-24 | English | ||
| 33035392 | 424B3 - Cingulate Inc. (0001862150) (Filer) | 2026-03-24 | English | ||
| 33013414 | S-3/A - Cingulate Inc. (0001862150) (Filer) | 2026-03-23 | English | ||
| 32974925 | 8-K - Cingulate Inc. (0001862150) (Filer) | 2026-03-18 | English | ||
| 32900022 | DEF 14A - CINGULATE INC. (0001862150) (Filer) | 2026-03-02 | English | ||
| 32111814 | 8-K Filing | 2026-02-17 | English | ||
| 32111863 | 4 Filing | 2026-02-10 | English | ||
| 32111808 | 4 Filing | 2026-02-10 | English | ||
| 32111782 | 4 Filing | 2026-02-10 | English | ||
| 32111778 | 4 Filing | 2026-02-10 | English | ||
| 32111823 | SCHEDULE 13D Filing | 2026-02-09 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Cingulate Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34936/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34936 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34936 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34936 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34936}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cingulate Inc. (id: 34936)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.